IP Verse

Astrazeneca Ab competitive analysis

Loading summary...

Latest patents of Astrazeneca Ab opposed by its competitors

Explore Astrazeneca Ab's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 6, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4188389
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With Dapagliflozin1
EP3045466
Oct 16, 2024(2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes1
EP4114465
Aug 30, 2023Anti-Ifnar1 Dosing Regime For Subcutaneous Injection1
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3769781
Apr 19, 2023Stable Anti-Ifnar1 Formulation1
EP2785349
Nov 9, 2022Combination Treatment Of Cancer1
EP3142661
Oct 6, 2021Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor1
EP2139494
Mar 11, 2020Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate6
EP3363807
Nov 13, 2019Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate1
EP2498759
Aug 1, 2018Immediate Release Tablet Formulations4

Latest PTAB cases involving Astrazeneca Ab

Discover the latest PTAB cases involving Astrazeneca Ab, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 9, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astrazeneca Ab

IPR2017-01910Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01912Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-01913Aug 4, 2017FRESENIUS KABI USAASTRAZENECA ABInstitution Denied
IPR2017-00900Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00904Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00905Feb 17, 2017INNOPHARMA LICENSINGASTRAZENECA ABInstitution Denied
IPR2017-00631Jan 9, 2017COMPLEX INNOVATIONSASTRAZENECA ABInstitution Denied
IPR2016-01316Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled
IPR2016-01324Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABTerminated-Settled
IPR2016-01325Jun 29, 2016MYLAN PHARMACEUTICALSASTRAZENECA ABInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astrazeneca Ab with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ASTRAZENECA - 27 - -
GALENICUM HEALTH SLU2713 - -
GEDEON RICHTER3 - - -
GENERICS UK214 - - -